Biodesix reports record full-year 2021 revenue of $54.5M; core lung diagnostic testing up 49%

BIODESIX INC

2022-FY EPS reported -$1.58 revenue$54,506,000

Full-year 2021 total revenue $54.5M vs $45.6M in 2020; Q4 revenue $7.2M.
Core lung diagnostic testing revenue grew 49% YoY; excluding COVID-19, annual core revenue $24.3M (+41%).
Q4 core revenue (ex-COVID) $6.8M, up 22% YoY and 13% sequentially.
Cash and cash equivalents $32.7M as of Dec 31, 2021.
CEO highlights new IQLung and GeneStrat NGS tests; company may seek additional capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.